Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V J Marder

Circulation

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Circulation|January 1, 1992
Inhibiting the inhibitorV J Marder
Circulation|October 1, 1990
What does the "Dimertest" test?V J Marder
Circulation|August 1, 1983
Pharmacology of thrombolytic agents. Implications for therapy of coronary artery thrombosisV J Marder
Circulation|March 1, 1995
Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit modelM Montoney, S J Gardell, V J Marder
Circulation|November 1, 1986
Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarctionC W Francis, D G Connaghan, V J Marder
Circulation|June 1, 1987
Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarctionC W Francis, D G Connaghan, W L Scott, et al.
Circulation|March 1, 1989
Increased immunoreactivity of plasma after fibrinolytic activation in an anti-DD ELISA system. Role of soluble crosslinked fibrin polymersC W Francis, K Doughney, B Brenner, et al.
Circulation|August 1, 1993
Comparison of native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant prophylaxisA Kornberg, C W Francis, V D Pellegrini, et al.
Circulation|March 1, 1985
Relationship of the lytic state to successful reperfusion with standard- and low-dose intracoronary streptokinaseR L Rothbard, P G Fitzpatrick, C W Francis, et al.
Circulation|June 1, 1990
Quantitation of venous clot lysis with the D-dimer immunoassay during fibrinolytic therapy requires correction for soluble fibrin degradationB Brenner, C W Francis, S Totterman, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Circulation|January 1, 1992
Inhibiting the inhibitorV J Marder
Circulation|October 1, 1990
What does the "Dimertest" test?V J Marder
Circulation|August 1, 1983
Pharmacology of thrombolytic agents. Implications for therapy of coronary artery thrombosisV J Marder
Circulation|March 1, 1995
Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit modelM Montoney, S J Gardell, V J Marder
Circulation|November 1, 1986
Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarctionC W Francis, D G Connaghan, V J Marder
Circulation|June 1, 1987
Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarctionC W Francis, D G Connaghan, W L Scott, et al.
Circulation|March 1, 1989
Increased immunoreactivity of plasma after fibrinolytic activation in an anti-DD ELISA system. Role of soluble crosslinked fibrin polymersC W Francis, K Doughney, B Brenner, et al.
Circulation|August 1, 1993
Comparison of native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant prophylaxisA Kornberg, C W Francis, V D Pellegrini, et al.
Circulation|March 1, 1985
Relationship of the lytic state to successful reperfusion with standard- and low-dose intracoronary streptokinaseR L Rothbard, P G Fitzpatrick, C W Francis, et al.
Circulation|June 1, 1990
Quantitation of venous clot lysis with the D-dimer immunoassay during fibrinolytic therapy requires correction for soluble fibrin degradationB Brenner, C W Francis, S Totterman, et al.
Pageof 2